Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lothar Seefried

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 14, 2025
A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosisLothar Seefried, Serge Ferrari, Dénes Páll, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 25, 2026
Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phaseSerge Ferrari, Lothar Seefried, Dénes Páll, et al.
The Journal of Clinical Investigation|April 25, 2017
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasiaLothar Seefried, Jasmin Baumann, Sarah Hemsley, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 15, 2026
XLH Matters 2024 GCC Edition: Insights and Recommendations to Improve Outcomes for People Living With XLH in the Gulf RegionLothar Seefried, Maryam Al Badi, Hasan Frookh, et al.
Clinical and Translational Science|February 18, 2026
A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult MalesEmmanuel Biver, Jean-Jacques Body, Ashwin Sachdeva, et al.
Orphanet Journal of Rare Diseases|March 8, 2024
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registryPriya S Kishnani, Gabriel Ángel Martos-Moreno, Agnès Linglart, et al.
Plos One|October 3, 2012
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitorsPeggy Benisch, Tatjana Schilling, Ludger Klein-Hitpass, et al.
American Journal of Medical Genetics. Part A|June 17, 2024
New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP RegistryPriya S Kishnani, Lothar Seefried, Kathryn M Dahir, et al.
Journal of Medical Genetics|February 18, 2025
Disease burden by <i>ALPL</i> variant number in patients with non-life-threatening hypophosphatasia in the Global HPP RegistryPriya S Kishnani, Lothar Seefried, Kathryn M Dahir, et al.
Clinical Orthopaedics and Related Research|March 24, 2023
Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized TrialMarc Jayankura, Thierry Thomas, Lothar Seefried, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 14, 2025
A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosisLothar Seefried, Serge Ferrari, Dénes Páll, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 25, 2026
Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phaseSerge Ferrari, Lothar Seefried, Dénes Páll, et al.
The Journal of Clinical Investigation|April 25, 2017
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasiaLothar Seefried, Jasmin Baumann, Sarah Hemsley, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 15, 2026
XLH Matters 2024 GCC Edition: Insights and Recommendations to Improve Outcomes for People Living With XLH in the Gulf RegionLothar Seefried, Maryam Al Badi, Hasan Frookh, et al.
Clinical and Translational Science|February 18, 2026
A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult MalesEmmanuel Biver, Jean-Jacques Body, Ashwin Sachdeva, et al.
Orphanet Journal of Rare Diseases|March 8, 2024
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registryPriya S Kishnani, Gabriel Ángel Martos-Moreno, Agnès Linglart, et al.
Plos One|October 3, 2012
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitorsPeggy Benisch, Tatjana Schilling, Ludger Klein-Hitpass, et al.
American Journal of Medical Genetics. Part A|June 17, 2024
New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP RegistryPriya S Kishnani, Lothar Seefried, Kathryn M Dahir, et al.
Journal of Medical Genetics|February 18, 2025
Disease burden by <i>ALPL</i> variant number in patients with non-life-threatening hypophosphatasia in the Global HPP RegistryPriya S Kishnani, Lothar Seefried, Kathryn M Dahir, et al.
Clinical Orthopaedics and Related Research|March 24, 2023
Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized TrialMarc Jayankura, Thierry Thomas, Lothar Seefried, et al.
Pageof 8